Compare Mesoblast Limited (MESO) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs iShares Silver Trust — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while iShares Silver Trust trades at $53.12. The key difference: Mesoblast Limited is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| MESO | SLV | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | — |
52-Week High | $20.96 | $105.57 |
52-Week Low | $12.88 | $33.32 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
SLV, the iShares Silver Trust ETF, trades at $50.98 with a slight 0.39% daily gain. The technical outlook is bearish, with moving averages signaling strong selling pressure and oscillators neutral. Recent news highlights silver's dual role as a monetary and industrial metal, with supply deficits and geopolitical tensions influencing prices. Financial ratios are not applicable as SLV is a commodity trust tracking silver prices, not a company with earnings.
The outlook for SLV hinges on silver's price trajectory, supported by industrial demand and supply constraints but pressured by Fed policy and dollar strength. Risks include volatility from macroeconomic shifts and competition from other silver ETFs like SIVR. Analyst sentiment is mixed, with silver's performance lagging gold year-to-date, yet long-term demand drivers remain intact.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
